Published • loading... • Updated
Valgen’s DragonFly TMVR System Receives CE Mark Approval for FMR Indication
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Valgen’s DragonFly TMVR System Receives CE Mark Approval for FMR Indication
June 26, 2026—Valgen Medtech, based in Hangzhou, China, recently announced that its DragonFly transcatheter mitral valve repair system has received European CE Mark approval for the treatment of functional mitral regurgitation (FMR). In April 2025, the device received European approval for degenerative mitral regurgitation (DMR), noted Valgen. The company advised that DragonFly has received regulatory approvals in 15 countries and regions with …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
